ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Venus Concept Inc

Venus Concept Inc (VERO)

0.691
-0.029
(-4.03%)
Closed March 28 04:00PM
0.70
0.009
(1.30%)
After Hours: 07:59PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.691
Bid
0.5609
Ask
0.7358
Volume
36,718
0.68 Day's Range 0.757
0.6015 52 Week Range 4.52
Market Cap
Previous Close
0.72
Open
0.757
Last Trade
22
@
0.6565
Last Trade Time
Financial Volume
$ 26,310
VWAP
0.716531
Average Volume (3m)
599,240
Shares Outstanding
5,529,149
Dividend Yield
-
PE Ratio
-0.09
Earnings Per Share (EPS)
-7.9
Revenue
99.5M
Net Profit
-43.7M

About Venus Concept Inc

Venus Concept Inc is a medical technology company. It develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Ve... Venus Concept Inc is a medical technology company. It develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Heal, Venus Bliss, ARTAS systems and others. The company provides medical devices and treatments for hair, body, and skin related problems. It operates in the U.S. as well as in other international countries. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Wilmington, Delaware, USA
Founded
1970
Venus Concept Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker VERO. The last closing price for Venus Concept was $0.72. Over the last year, Venus Concept shares have traded in a share price range of $ 0.6015 to $ 4.52.

Venus Concept currently has 5,529,149 shares outstanding. The market capitalization of Venus Concept is $3.87 million. Venus Concept has a price to earnings ratio (PE ratio) of -0.09.

VERO Latest News

Venus Concept Granted Continued Listing from Nasdaq Hearings Panel, Subject to Return to Compliance with Nasdaq Listing Rules

TORONTO, March 25, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO) announced today that it received a decision from the Nasdaq Hearings Panel (the...

Venus Concept Launches “NEXThetics” Program

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic technology leader, announces the launch of...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934   (Amendment No...

Form 8-K - Current report

false0001409269NASDAQ00014092692024-02-222024-02-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K CURRENT...

Venus Concept Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has closed...

Form 424B5 - Prospectus [Rule 424(b)(5)]

TABLE OF CONTENTSFiled pursuant to Rule 424(b)(5)Registration No. 333-260267Prospectus SupplementTo Prospectus dated October 25, 2021 Venus Concept Inc.817,748 Shares of Common StockWe...

Venus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

TORONTO, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.0213.134328358210.670.770.6105154460.70460988CS
4-0.149-17.73809523810.840.89990.6015337300.75433566CS
12-0.429-38.30357142861.122.2150.60155992401.78605525CS
26-1.349-66.12745098042.042.430.60152822811.78345971CS
52-2.009-74.40740740742.74.520.60151898732.15039171CS
156-33.959-98.005772005834.6550.550.601542671411.31982417CS
260-77.309-99.1141025641781350.601538941918.53960724CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

VERO Discussion

View Posts
Monksdream Monksdream 2 weeks ago
VERO new 52 week lo
👍️0
Invest-in-America Invest-in-America 1 month ago
VERO: Cute nomenclature for a routine to fix flucked-up Human SKIN!!! ("VENUS"; heck, in the EU now they can call it "VENUS DE MILO!!")
👍️0
Awl416 Awl416 1 month ago
Venus Concept Announces CE Mark for Venus Versa Pro in Europe
👍️0
Triple nickle Triple nickle 11 months ago
Building up steam
👍️0
Triple nickle Triple nickle 11 months ago
It went positive yesterday
👍️0
Triple nickle Triple nickle 11 months ago
Buy rating to 2.20
👍️0
Triple nickle Triple nickle 11 months ago
Adding
👍️0
81vette 81vette 1 year ago
finally, accumulation started,seller/debt might be done,its moving better now
👍️0
81vette 81vette 1 year ago
Shares outstanding 67m,volume today 78m,lots of bills paid today,future looking good with many other news worthy products in pipeline
👍️0
81vette 81vette 1 year ago
$29.5m traded today(record high),follow the money,monthly trend so far
👍️0
81vette 81vette 1 year ago
gap filled,rsi bouncing off oversold,loading zone now
👍️0
81vette 81vette 1 year ago
300Xs ave volume,at least 10x pps should follow
👍️0
81vette 81vette 1 year ago
zero borrow,no shares to short>12.83% 0.00% 0 2022-12-21 10:45:03
12.83% 0.00% 0 2022-12-21 10:30:03
12.83% 0.00% 0 2022-12-21 10:15:03
12.83% 0.00% 0 2022-12-21 10:00:03
12.83% 0.00% 0 2022-12-21 09:45:03
12.83% 0.00% 0 2022-12-21 09:30:03
12.83% 0.00% 0 2022-12-21 09:15:04
12.83% 0.00% 0 2022-12-21 09:00:03
12.83% 0.00% 0 2022-12-21 08:45:04
12.83% 0.00% 0 2022-12-21 08:30:03
12.83% 0.00% 0 2022-12-21 08:15:03
12.83% -8.51% 75000 2022-12-21 08:00:03
12.83% -8.51% 850000 2022-12-20 17:45:03
12.83% -8.51% 850000 2022-12-20 17:30:04
12.83% -8.51% 850000 2022-12-20 17:15:03
12.83% -8.51% 850000 2022-12-20 17:00:04
12.83% -8.51% 850000 2022-12-20 16:45:04
👍️0
81vette 81vette 1 year ago
FDA news this big should run many days
👍️0
subslover subslover 1 year ago
Venus Concept Receives 510(k) Clearance for Use of its AI.ME™ Next Generation Robotic Technology for Fractional Skin Resurfacing
December 21 2022 - 07:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received a 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its AI.ME next generation robotic technology for fractional skin resurfacing.

“We are very pleased to receive the first FDA regulatory clearance for our non-surgical robotic technology platform, AI.ME, and believe it showcases Venus Concept’s ongoing investment in technology, innovation, and clinical research towards robotics applications in the field of medical aesthetics,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “AI.ME is a first-of-its-kind robotic platform offering physicians minimally-invasive treatments for high-demand procedures requiring fractional skin resurfacing. We see AI.ME as a versatile platform and we will continue to develop the platform to provide innovative solutions in various areas of medical aesthetics, starting with fractional skin resurfacing. The AI.ME technology will be critical to maximizing the synergy between our well-established medical aesthetic business and our pioneering robotics business driven by a robust R&D pipeline developed by our team in San Jose. This 510(k) clearance brings us one step closer to our goal of commercializing AI.ME in the U.S., and we look forward to introducing our first AI.ME systems with Venus Concept’s leading physician partners in 2023.”

The AI.ME robotic system utilizes an advanced visualization system, machine vision, and Artificial Intelligence algorithms to target the dermis in a pre-planned selective, and predictable manner. It uses a smart array of micro-coring hollow punches to precisely core and excise micro-skin fractions at a precise depth to remove up to 10% of skin in the treatment area, leading to collagen deposition and fractional skin resurfacing of the treated area.

“Integrating the advancements of robotics into the area of minimally-invasive aesthetic procedures is very promising,” said Girish (Gilly) Munavalli, MD, MHS, FACMS board-certified dermatologist and advisor to Venus Concept. “This new technology may become a real game-changer in the area of medical aesthetics, offering a new level of consistency, predictability, and visualization which will differentiate it from existing energy-based solutions. We had the privilege to participate in the early clinical studies of AI.ME and it is clear that the advancements that its robotic technology presents to our practice can go far beyond fractional skin resurfacing. I’m encouraged to see some true innovation in the area of minimally-invasive aesthetic treatments and I’m looking forward to seeing the technology evolve to produce consistent transformational results.”

About Venus Concept

Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 16 direct markets. Venus Concept’s product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Venus Concept’s hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners, and Masters Special Situations.

Cautionary Statement Regarding Forward-Looking Statements
👍️0
reena969 reena969 1 year ago
..64 = 100%
👍️0
reena969 reena969 1 year ago
FDA news $$$
👍️0
DK11 DK11 1 year ago
I thought this stock was about to show promise, maybe not
👍️0
DK11 DK11 1 year ago
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001409269/000143774922026907/vero20220930_10q.htm
Is this stock going to be de-listed from Nasdaq read page 58.???
👍️0
DK11 DK11 1 year ago
This is super tight it has to go. Ready to explode
👍️0
INFINITI INFINITI 1 year ago
Super thin here$$$
👍️0
INFINITI INFINITI 1 year ago
Should be an awsome week $$$$
👍️0
INFINITI INFINITI 1 year ago
Looking good here I’m in $$$$$
👍️0
Zardiw Zardiw 2 years ago
#DDAmanda Chart on: $VERO :

You can scan for these before they run.



#DDAmanda is still the best way to find #WinningStocks before they run.
Contact/Text: 760 702-2009

What the Fact (Factor) Column is:

The Factor is a proprietary indicator used for scanning in #DDAmanda.

It's defined as Today's $Traded divided by the average daily $Traded (20 day avg).

SO, if a stock has say a 10 Factor that day, it means she traded 10 Times the $ she normally trades.

That's significant, and many times indicates that a run in the stock is coming.






Z
👍️0
lecorb lecorb 3 years ago
First rating to update target price today!
Marie Thibault
BTIG
4.5 Stars
target
$7.00
ranking
Buy
analystAction
Reiterated
date
14 hours ago
TDAmeritrade Inc.
👍️0
lecorb lecorb 3 years ago
Venus Concept Stock Trades Higher After Lifting FY21 Sales Outlook
11:19 am ET August 13, 2021 (Benzinga) Print
Venus Concept Inc's (NASDAQ: VERO) Q2 sales increased 52% Y/Y to $25.8 million, beating the consensus of $24.26 million.
The increase by product category was driven by a 71% increase in lease revenue, a 29% increase in systems revenue, an 86% increase in products revenue, and a 5% increase in services revenue.
The gross margin improved to 72.5% from 70.0%, primarily driven by higher sales of Venus consumables and improved revenue mix of system sales sold under our subscription program, tracing to Venus Bliss.
Operating income increased 117% Y/Y to $1.5 million compared to a loss of $(8.8) million a year ago.
EPS of $0.01 improved from a loss of $(0.39) and ahead of analyst estimate loss of $(0.12).
FY21 Guidance: Venus expects sales of $102 million - $107 million, representing a 31% - 37% Y/Y increase, better than the Wall Street estimate of $103.24 million.
Prior sales estimate were $100 million - $105 million, +28% to 35%, Y/Y.
Price Action: VERO shares are up 1.91% at $2.13 during the market session on the last check Friday.
👍️0
lecorb lecorb 3 years ago
NSTITUTIONAL OWNERSHIP CHANGES (13F FILINGS) FOR VENUS CONCEPT (NASDAQ:VERO)
Institutional Ownership Percentage: 43.04%

8/13/2021 Vanguard Group Inc. 1,011,657 $3.15M 0.0% +3.4% 1.871%
8/12/2021 Dimensional Fund Advisors LP 116,052 $0.36M 0.0% +29.8% 0.215%
8/12/2021 Essex Investment Management Co. LLC 733,425 $2.28M 0.3% +47.2% 1.356%
8/12/2021 Ergoteles LLC 107,516 $0.33M 0.0% N/A 0.199%
8/11/2021 Bank of New York Mellon Corp 36,048 $0.11M 0.0% -57.4% 0.067%
8/11/2021 Deutsche Bank AG 59,500 $0.19M 0.0% +396.7% 0.110%
8/11/2021 Susquehanna Fundamental Investments LLC 13,000 $40K 0.0% N/A 0.024%
8/3/2021 Oppenheimer & Co. Inc. 15,500 $48K 0.0% N/A 0.029%
👍️0
makinezmoney makinezmoney 3 years ago
$VERO: My bad...... $25.8MIlly in QUARTERLY REVS

And Venus Williams ?????????


WOW


Cheap here at $2.10 now


Confidence is Venus Williams' secret to looking and feeling her best. In this master video, watch as Venus explains all the reasons why she loves Venus Bliss™! https://t.co/37CHKiwSDd— Venus Aesthetic Intelligence (@Venus_A_I) August 3, 2021











GO $VERO
👍️0
lecorb lecorb 3 years ago
When they double their target price, possibly the monday more than one compulsive short seller will cry a lot

Marie Thibault
BTIG
StarStarStarStarStar
target
$7.00
ranking
Buy
analystAction
Reiterated
date
2 months ago


Anthony Vendetti
Maxim Group
StarStarStarStarStar
target
$6.00
ranking
Buy
analystAction
Reiterated
date
3 months ago


Suraj Kalia
Oppenheimer
StarStarStarStarStar
target
$4.00
ranking
Buy
analystAction
Maintained
date
3 months ago
👍️0
makinezmoney makinezmoney 3 years ago
$VERO: Solid Earnings report......... $2.58Milly quarterly revs


BRIEF-Venus Concept Announces Second Quarter 2021 Financial Results Increases Fiscal Year 2021 Revenue Guidance
7:14 AM ET 8/13/21 | Reuters
BRIEF-Venus Concept Announces Second Quarter 2021 Financial Results Increases Fiscal Year 2021 Revenue Guidance
Aug 13 (Reuters) - Venus Concept Inc:

* VENUS CONCEPT ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS; INCREASES FISCAL YEAR 2021 REVENUE GUIDANCE

* Q2 REVENUE $25.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $24.3 MILLION

* SEES FY 2021 REVENUE UP ABOUT 31 TO 37 PERCENT

* SEES FY 2021 REVENUE $102 MILLION TO $107 MILLION

* FY2021 REVENUE VIEW $103.2 MILLION -- REFINITIV IBES DATA

* Q2 EARNINGS PER SHARE $0.01

* Q2 EARNINGS PER SHARE VIEW $-0.12 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:



GO $VERO
👍️0
OR Nurse OR Nurse 3 years ago
CRNA. You don't think you can sneak into VERO headquarters and snap a few photos and see if you see anything can you? Perhaps post them here. Asking for a friend. lol
👍️0
OR Nurse OR Nurse 3 years ago
CRNA. You don't think you can sneak into VERO headquarters and snap a few photos and see if you see anything can you? Perhaps post them here. Asking for a friend.
👍️0
Adrock Adrock 3 years ago
HAIR OUT THE ENOS pal!!

👍️0
BigT82 BigT82 3 years ago
Growing BIG after hours pal!

To da mooooon!!
👍️0
Adrock Adrock 3 years ago
SCOOOOOOOOOOOOP DAT HAIR GROWTH!
👍️0
BigT82 BigT82 3 years ago
Nice pop! Let’s goooo!

Huge Monday news coming!

Merger Monday!?
👍️0
Adrock Adrock 3 years ago
Scooooooooooooooop Em!!!
👍️0
BigT82 BigT82 3 years ago
Moving on up! Let’s gooo!
👍️0
CRNA CRNA 4 years ago
Isn’t anybody excited about zaring. Scoping out the company for Medtronic for a buyout
👍️0
Roadtojourney Roadtojourney 4 years ago
Ofcouse imo
👍️0
Roadtojourney Roadtojourney 4 years ago
This was higher few days back even before this fluff news
👍️0
Roadtojourney Roadtojourney 4 years ago
Makes no sense volume was more yesterday AH
👍️0
saigai saigai 4 years ago
volume is awesome...
👍️0
Roadtojourney Roadtojourney 4 years ago
Why is it not flying?? The news is good the stock is good too??
👍️0
Roadtojourney Roadtojourney 4 years ago
And down it goes
👍️0
boston127 boston127 4 years ago
Starts out slow every AM.

I have noticed this trend. Thus, I pick up an additional 100-200 shares in the AM and do not get flustered with momentary ups and downs. The trend is our friend.
👍️0
boston127 boston127 4 years ago
Venus Concept started at outperform

with $15 stock price target at Oppenheimer (1-10-2020). They are a very credible investment firm. Think I will hang in here for awhile.
👍️0
boston127 boston127 4 years ago
Nice move up today.

I doubled up my holdings this AM, just as it hit the high of the day. ): That's OK. This is a keeper. The products are great.

Fiscal Year 2020 Revenue Guidance:

Total revenue for the twelve months ended December 31, 2020 is expected to be in the range of $134.0 million to $140.0 million. The Company’s fiscal year 2020 revenue guidance range represents projected growth of approximately 9% to 13% year-over-year as compared to the preliminary total revenue range, on a pro-forma basis, of $122.6 million to $123.5 million for the twelve months ended December 31, 2019.
👍️0

Your Recent History

Delayed Upgrade Clock